DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/jxbpmg/acute_respiratory) has announced the addition of GlobalData's new report "Acute Respiratory Distress Syndrome (ARDS) Therapeutics - Pipeline Assessment and Market Forecasts to 2019" to their offering.
Weak Pipeline Means No Breath of Fresh Air for Acute Respiratory Distress Treatment Market.
Physicians are not holding their breath for the launch of new revolutionary treatments for acute respiratory distress syndrome (ARDS) in the near future, according to a new report by healthcare intelligence experts GlobalData.
The new report* shows that current drug research being made into the area by pharmaceutical companies has failed to reach the late stages of development, leaving patients without new treatments for this severe and often fatal condition.
ARDS is a reaction to a serious injury or infection in the lung, which leads to inflammation and impaired gas exchange, and can result in multiple organ failure. Mechanical ventilation and admission to an intensive care unit is generally required, but the condition can often be fatal.
While modern pharmacological treatment options are available to cure certain conditions that sometimes lead to ARDS, such as sepsis and pneumonia, currently there is no cure for ARDS itself. Instead, available treatment options only provide supportive treatment such as mechanical ventilation, positive end-expiratory pressure (PEEP) and low tidal volume ventilation, which all help to increase oxygen supply to the lungs.
There are no approved drugs for ARDS in the US or Europe, though Elaspol (sivelestat sodium hydrate) was approved for ARDS in Japan in 2002. Despite this clear gap in the market for effective treatments, there are no upcoming drugs in the late stage of the development pipeline.
GlobalData estimates that the global ARDS therapeutics market was worth $612m in 2011, and forecasts growth at a Compound Annual Growth Rate (CAGR) of 1.3% to reach $681.1m by 2019. The market therefore offers huge potential for new drug entrants that can provide an improved safety profile.
- Altor BioSciences
- Faron Pharmaceuticals, Ltd.
For more information visit http://www.researchandmarkets.com/research/jxbpmg/acute_respiratory